Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
10.00
+0.07 (0.70%)
At close: Mar 19, 2026, 4:00 PM EDT
10.00
0.00 (0.00%)
After-hours: Mar 19, 2026, 4:02 PM EDT
Relay Therapeutics Revenue
In the year 2025, Relay Therapeutics had annual revenue of $15.36M with 53.44% growth. Relay Therapeutics had revenue of $7.00M in the quarter ending December 31, 2025.
Revenue (ttm)
$15.36M
Revenue Growth
+53.44%
P/S Ratio
115.93
Revenue / Employee
$79,974
Employees
192
Market Cap
1.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.36M | 5.35M | 53.44% |
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Aurinia Pharmaceuticals | 283.06M |
| AnaptysBio | 234.60M |
| Soleno Therapeutics | 190.41M |
| Zymeworks | 105.97M |
| Recursion Pharmaceuticals | 74.68M |
| Mesoblast | 65.38M |
| Agios Pharmaceuticals | 54.03M |
RLAY News
- 3 days ago - Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients? - Benzinga
- 3 days ago - Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - GlobeNewsWire
- 20 days ago - Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - GlobeNewsWire
- 23 days ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - GlobeNewsWire
- 27 days ago - Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 6 weeks ago - Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 3 months ago - Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 - GlobeNewsWire